Clinical observation of glutathione to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive / 中国基层医药

ABSTRACT

Objective To observe the clinical efficacy of glutathione(GSH)to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.Methods 164 cases with hepatitis B markers positive were selected and divided into the treatment group(82 cases)and control group(82 cases).In a statin therapy with primary disease,at the same time,the control group using based protect liver therapy(both inosine,vitamin C),the treatment group using reduced glutathione intravenous drip(1.2g,one/d).After 12 weeks,the liver function was examined.Results Patients taking statins ALT,TB and DB levels obviously higher than before,had a statistically significant difference(t=2.66,1.98,2.13,P＜0.05),the differences of observation index level in treatment group before and after treatment had no statistical difference(P＞0.05),12 patients(14.6％)ALT level in treatment group were more than normal,0 case more than normal limit 3 times,control group respectively for 23 cases(28.1％),3 cases(3.7％),two groups had statistically significant difference(x2=4.672,5.304,all P＜0.05).Conclusion GSH can obviously reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.